Related Experiment Video
Updated: Aug 10, 2026
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Heparin-induced thrombocytopenia in pediatrics
Insights
Heparin-induced thrombocytopenia (HIT) type II is a serious risk for pediatric patients receiving heparin for thrombosis. HIT type II in children and adolescents requires careful consideration due to severe complications.
Area of Science:
- Pediatric Hematology
- Thrombosis and Hemostasis
- Pharmacology
Background:
- Heparin is crucial for preventing and treating thromboembolism in pediatric patients.
- Heparin therapy carries a risk of heparin-induced thrombocytopenia (HIT), particularly HIT type II.
- Limited data exists on HIT type II in pediatric populations compared to adults.
Purpose of the Study:
- To review existing literature on HIT type II in pediatric patients.
- To present a case of recurrent thrombosis and HIT type II without thrombocytopenia in a child.
- To highlight the incidence, risk factors, and management of HIT type II in neonates, children, and adolescents.
Main Methods:
- Literature review of pediatric HIT type II cases.
- Case report of a pediatric patient with thrombosis and HIT type II.
- Analysis of age-specific incidence and clinical presentation.
Main Results:
- HIT type II predominantly affects neonates and adolescents, aligning with pediatric thrombosis peaks.
- Risk factors include hereditary predisposition, immobilization, and surgery.
- Severe complications, including life-threatening thromboembolism, were observed.
- Thrombocytopenia was absent in five reported cases.
- Heparin was often switched to danaparoid sodium or hirudin.
Conclusions:
- HIT type II is a significant and potentially dangerous complication of heparin use in pediatric patients.
- Clinicians must consider HIT type II in neonates, children, and adolescents receiving heparin.
- Early recognition and alternative anticoagulation are vital for managing HIT type II in this population.
Abstract:
As in adult patients, heparin is used for prophylaxis and treatment of thromboembolism in newborns, children, and adolescents. Patients receiving heparin are potentially at risk to develop heparin-induced thrombocytopenia (HIT). HIT type II has been extensively described in the adult population; only a few reports address HIT type II in pediatric patients (total of 15 neonates, 4 young children, 12 older children and adolescents). The available data are discussed, and the case of a patient with recurrent thrombosis and HIT type II without thrombocytopenia is presented. The review of the literature reveals that HIT type II occurs especially in neonates and adolescents, corresponding to the two age peaks of thrombosis in pediatric patients. Risk factors for thrombosis include hereditary factors, immobilization, and surgery. HIT complications are severe and partly lead to life-threatening thromboembolism. In three patients, an increasing heparin demand was found. In five cases, thrombocytopenia was absent. Heparin was replaced mostly by danaparoid sodium; in three patients hirudin was used as an alternative anticoagulant. HIT type II represents a potentially dangerous complication of heparin therapy in pediatric patients and should be taken into consideration whenever heparin is given for prophylactic or therapeutic use in newborns, children, or adolescents.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care